Evidence map›Paper›PMID 36611161›Full record

ArticleJournal of biomedical science2023

The miR-15b-Smurf2-HSP27 axis promotes pulmonary fibrosis.

Seulgi Jeon, Hee Jin, Jin-Mo Kim, Youmin Hur, Eun Joo Song, Yoon-Jin Lee, Younghwa Na, Jaeho Cho, Yun-Sil Lee

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. GTSE1-driven ZEB1 stabilization promotes pulmonary fibrosis through the epithelial-to-mesenchymal transition.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Crosstalk of ubiquitin system and non-coding RNA in fibrosis.International journal of biological sciences · 2024
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Seulgi Jeon *Graduate School of Pharmaceutical Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
Hee Jin *Graduate School of Pharmaceutical Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
Jin-Mo KimDepartment of Radiation Oncology, Yonsei University Health System, 50, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Youmin HurGraduate School of Pharmaceutical Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
Eun Joo SongGraduate School of Pharmaceutical Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
Yoon-Jin LeeKorea Institute of Radiological and Medical Science, Seoul, 01812, Republic of Korea.
Younghwa NaCollege of Pharmacy, CHA University, 120, Haeryong-ro, Pocheon-si, Gyeonggi-do, 11160, Republic of Korea. yna7315@cha.ac.kr.
Jaeho ChoDepartment of Radiation Oncology, Yonsei University Health System, 50, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. jjhmd@yuhs.ac.
Yun-Sil LeeGraduate School of Pharmaceutical Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea. yslee0425@ewha.ac.kr.
Ewha Womans University · KRKorea Institute of Radiological and Medical Sciences · KRYonsei University Health System · KRCHA University · KR

Funding

The National Research Foundation of Korea 2018R1A5A2025286The National Research Foundation of Korea 2020M2D9A2093974The National Research Foundation of Korea 2020M2D9A2093976The National Research Foundation of Korea 2020R1A2C3013255The National Research Foundation of Korea 2020R1I1A1A01070841The National Research Foundation of Korea 2022R1A2C3011611
6 · The paper itself

Abstract

backgroundHeat shock protein 27 (HSP27) is overexpressed during pulmonary fibrosis (PF) and exacerbates PF; however, the upregulation of HSP27 during PF and the therapeutic strategy of HSP27 inhibition is not well elucidated.

methodsWe have developed a mouse model simulating clinical stereotactic body radiotherapy (SBRT) with focal irradiation and validated the induction of RIPF. HSP25 (murine form of HSP27) transgenic (TG) and LLC1-derived orthotropic lung tumor models were also used. Lung tissues of patients with RIPF and idiopathic pulmonary fibrosis, and lung tissues from various fibrotic mouse models, as well as appropriated cell line systems were used. Public available gene expression datasets were used for therapeutic response rate analysis. A synthetic small molecule HSP27 inhibitor, J2 was also used.

resultsHSP27 expression with its phosphorylated form (pHSP27) increased during PF. Decreased mRNA expression of SMAD-specific E3 ubiquitin-protein ligase 2 (Smurf2), which is involved in ubiquitin degradation of HSP27, was responsible for the increased expression of pHSP27. In addition, increased expression of miRNA15b was identified with decreased expression of Smurf2 mRNA in PF models. Inverse correlation between pHSP27 and Smurf2 was observed in the lung tissues of PF animals, an irradiated orthotropic lung cancer models, and PF tissues from patients. Moreover, a HSP27 inhibitor cross-linked with HSP27 protein to ameliorate PF, which was more effective when targeting the epithelial to mesenchymal transition (EMT) stage of PF.

conclusionsOur findings identify upregulation mechanisms of HSP27 during PF and provide a therapeutic strategy for HSP27 inhibition for overcoming PF.

Indexed as

MicroRNAsPulmonary FibrosisAnimalsEpithelial-Mesenchymal TransitionHSP27 Heat-Shock ProteinsMiceRNA, MessengerUbiquitin-Protein LigasesHSP27 Heat-Shock ProteinsMicroRNAsRNA, MessengerUbiquitin-Protein LigasesHSP27miRNAPhosphorylationProtein degradationPulmonary fibrosisSmurf2

Identifiers

PMID36611161
PMCPMC9824921
OpenAlexW4313642858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.